RNF217-AS1 and urinary bladder carcinoma: This discerning finding not only highlights the potential therapeutic relevance of STL, PXT, and CMP in the context of bladder cancer treatment but also accentuates the prospect of targeted interventions leveraging these ligands to address the specific molecular landscape of the disease.